Current guidelines for high-density lipoprotein cholesterol in therapy and future directions

References

• BodenWEHigh-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High – Density Lipoprotein Intervention TrialAm J Cardiol20008612A19L22L
   Web of Science ®Google Scholar
• CampbellCYRiveraJJBlumenthalRSResidual risk in statin-treated patients: future therapeutic optionsCurr Cardiol Rep20079649950517999876
   PubMedGoogle Scholar
• Mahdy AliKWonnerthAHuberKWojtaJCardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunitiesBr J Pharmacol201216761177119422725625
   PubMed Web of Science ®Google Scholar
• AssmannGGottoAMJrHDL cholesterol and protective factors in atherosclerosisCirculation200410923 Suppl 1III8III1415198960
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCTreating to New Targets InvestigatorsHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• VoightBFPelosoGMOrho-MelanderMPlasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyLancet2012380984157258022607825
   PubMed Web of Science ®Google Scholar
• HafianeAGenestJHDL, Atherosclerosis, and emerging therapiesCholesterol2013201389140323781332
   PubMedGoogle Scholar
• LimSParkYMSakumaIKohKKHow to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterolInt J Cardiol2013166181422503572
   PubMed Web of Science ®Google Scholar
• HausenloyDJYellonDMEnhancing cardiovascular disease risk reduction: raising high-density lipoprotein levelsCurr Opin Cardiol200924547348219574922
   PubMed Web of Science ®Google Scholar
• GaoXYuanSHigh density lipoproteins-based therapies for cardiovascular diseaseJ Cardiovasc Dis Res2010139910321187875
   PubMedGoogle Scholar
• Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [webpage on the Internet]Bethesda, MDNational Heart, Lung, and Blood Institute, National Institutes of Health2002 [updated 2004]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/Accessed September 29, 2013
   Google Scholar
• JellingerPSSmithDAMehtaAEAACE Task Force for Management of Dyslipidemia and Prevention of AtherosclerosisAmerican Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summaryEndocr Pract201218226929322507559
   PubMedGoogle Scholar
• ReinerZCatapanoALDeBacker GEuropean Association for Cardiovascular Prevention and RehabilitationESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 CommitteesESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Eur Heart J201132141769181821712404
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTAIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVEBethesda, MDNational Institutes of Health2012 Available from: http://clinicaltrials.gov/ct2/show/NCT00461630Accessed December 6, 2013
   Google Scholar
• AndersonTJGrégoireJHegeleRA2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201329215116723351925
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJLichtensteinAH2013ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol Epub117 2013
   Google Scholar
• MinderCMBlahaMJHorneAMichosEDKaulSBlumenthalRSEvidence-based use of statins for primary prevention of cardiovascular diseaseAm J Med2012125544044622387091
   PubMed Web of Science ®Google Scholar
• WalldiusGJungnerIThe apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidenceJ Intern Med2006259549351916629855
   PubMed Web of Science ®Google Scholar
• MoutzouriEKeiAElisafMSMilionisHJManagement of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acidVasc Health Risk Manag2010652553920730069
   PubMedGoogle Scholar
• GinsbergHNElamMBLovatoLCACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• Bezafibrate Infarction Prevention (BIP) studySecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery diseaseCirculation20001021212710880410
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med198731720123712453313041
   PubMed Web of Science ®Google Scholar
• BrooksELKuvinJTKarasRHNiacin’s role in the statin eraExpert Opin Pharmacother201011142291230020569085
   PubMed Web of Science ®Google Scholar
• KheraAVPatelPJReillyMPRaderDJThe addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionalityJ Am Coll Cardiol201362201909191023933538
   PubMed Web of Science ®Google Scholar
• MichosEDSibleyCTBaerJTBlahaMJBlumenthalRSNiacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trialsJ Am Coll Cardiol201259232058206422520249
   PubMed Web of Science ®Google Scholar
• ConnollyBAO’ConnellDPLeBlancDFARI-3037MO, a novel niacin analog, significantly improves plasma lipid levels in the hyperlipidemic golden syrian hamsterCirculation2011124A18285
   Web of Science ®Google Scholar
• BlahaMJMichosEDNiacin – a case study for the role of event-driven versus surrogate endpoint trialsHeart201399221631163224041650
   PubMed Web of Science ®Google Scholar
• BarterPJBrewerHBJrChapmanMJHennekensCHRaderDJTallARCholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosisArterioscler Thromb Vasc Biol200323216016712588754
   PubMed Web of Science ®Google Scholar
• KaralisIRensenPCJukemaJWJourney through cholesteryl ester transfer protein inhibition: from bench to bedsideCirc Cardiovasc Qual Outcomes20136336036623674310
   PubMed Web of Science ®Google Scholar
• ShahPKNilssonJKaulSEffects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient miceCirculation19989787807859498542
   PubMed Web of Science ®Google Scholar
• NissenSETsunodaTTuzcuEMEffect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trialJAMA2003290172292230014600188
   PubMed Web of Science ®Google Scholar
• NichollsSJTuzcuEMSipahiIRelationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I MilanoJ Am Coll Cardiol200647599299716516083
   PubMed Web of Science ®Google Scholar
• IbanezBGiannarelliCCimminoGRecombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type)Atherosclerosis20122201727722030095
   PubMed Web of Science ®Google Scholar
• TardifJCGrégoireJL’AllierPLEffect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) InvestigatorsEffects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trialJAMA2007297151675168217387133
   PubMed Web of Science ®Google Scholar
• ChenevardRHürlimannDSpiekerLReconstituted HDL in acute coronary syndromesCardiovasc Ther2012302e51e5720840194
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]A single ascending dose study examining the safety and pharmacokinetic profile of reconstituted high density lipoprotein (CSL112) administered to patientsBethesda, MDNational Institutes of Health2011 [updated January 8, 2014]. Available from: http://clinicaltrials.gov/show/NCT01499420Accessed September 28, 2013
   Google Scholar
• Product development is innovation [webpage on the Internet]Parsipanny, NJThe Medicines Company2014 Available from: http://www.themedicinescompany.com/page/pipelineAccessed January 1, 2014
   Google Scholar
• SacksFMRudelLLConnerASelective delipidation of plasma HDL enhances reverse cholesterol transport in vivoJ Lipid Res200950589490719144994
   PubMed Web of Science ®Google Scholar
• DegomaEMRaderDJNovel HDL-directed pharmacotherapeutic strategiesNat Rev Cardiol20118526627721243009
   PubMed Web of Science ®Google Scholar
• WaksmanRTorgusonRKentKMA first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndromeJ Am Coll Cardiol201055242727273520538165
   PubMed Web of Science ®Google Scholar
• VedhachalamCLiuLNickelMInfluence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipidsJ Biol Chem200427948499314993915383537
   PubMed Web of Science ®Google Scholar
• BloedonLTDunbarRDuffyDSafety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsJ Lipid Res20084961344135218323573
   PubMed Web of Science ®Google Scholar
• WeihrauchDXuHShiYEffects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin miceAm J Physiol Heart Circ Physiol20072933H1432H144117496220
   PubMed Web of Science ®Google Scholar
• NavabMReddySTAnantharamaiahGMD-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null miceJ Lipid Res201253343744522167743
   PubMed Web of Science ®Google Scholar
• NavabMReddySTAnantharamaiahGMIntestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orallyJ Lipid Res20115261200121021444758
   PubMed Web of Science ®Google Scholar
• ChattopadhyayANavabMHoughGA novel approach to oral apoA-I mimetic therapyJ Lipid Res2013544995101023378594
   PubMed Web of Science ®Google Scholar
• TabetFRemaleyATSegalinyAIThe 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitroArterioscler Thromb Vasc Biol201030224625219965776
   PubMed Web of Science ®Google Scholar
• Di BartoloBANichollsSJBaoSThe apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteinsAtherosclerosis2011217239540021571275
   PubMed Web of Science ®Google Scholar
• BielickiJKZhangHCortezYA new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in miceJ Lipid Res20105161496150320075422
   PubMed Web of Science ®Google Scholar
• SrivastavaRAEvaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis- susceptible F(1)B hamstersAtherosclerosis20112141869321093860
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKEffects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trialsJAMA2007297121362137317384435
   PubMed Web of Science ®Google Scholar
• BergerJPAkiyamaTEMeinkePTPPARs: therapeutic targets for metabolic diseaseTrends Pharmacol Sci200526524425115860371
   PubMed Web of Science ®Google Scholar
• HenryRRLincoffAMMudaliarSRabbiaMChognotCHerzMEffect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyLancet2009374968412613519515415
   PubMed Web of Science ®Google Scholar
• TangNPWangLSYangLProtective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese populationJ Lipid Res200849236937517986713
   PubMed Web of Science ®Google Scholar
• GoodmanKBBuryMJCheungMDiscovery of potent, selective sulfonylfuran urea endothelial lipase inhibitorsBioorg Med Chem Lett2009191273019058966
   PubMed Web of Science ®Google Scholar
• BaileyDJahagirdarRGordonARVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivoJ Am Coll Cardiol201055232580258920513599
   PubMed Web of Science ®Google Scholar
• NichollsSJGordonAJohanssonJEfficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trialJ Am Coll Cardiol20115791111111921255957
   PubMed Web of Science ®Google Scholar
• Resverlogix announces two new findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability. [webpage on the Internet]Calgary, ABResverlogix Corporation2013 Available from: http://www.resverlogix.com/media/press-release.html?id=494#.UximyvldUWYAccessed January 1, 2014
   Google Scholar
• RoussetXVaismanBAuerbachBEffect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in miceJ Pharmacol Exp Ther2010335114014820605907
   PubMed Web of Science ®Google Scholar
• RoussetXShamburekRVaismanBAmarMRemaleyATLecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?Curr Atheroscler Rep201113324925621331766
   PubMed Web of Science ®Google Scholar
• BełtowskiJLiver X receptors (LXR) as therapeutic targets in dyslipidemiaCardiovasc Ther200826429731619035881
   PubMed Web of Science ®Google Scholar
• CalkinACTontonozPLiver X receptor signaling pathways and atherosclerosisArterioscler Thromb Vasc Biol20103081513151820631351
   PubMed Web of Science ®Google Scholar
• KatzAUdataCOttESafety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participantsJ Clin Pharmacol200949664364919398602
   PubMed Web of Science ®Google Scholar
• MencarelliAFiorucciSFXR an emerging therapeutic target for the treatment of atherosclerosisJ Cell Mol Med2010141–2799220041971
   PubMed Web of Science ®Google Scholar
• GaudetDMéthotJDérySEfficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trialGene Ther201320436136922717743
   PubMed Web of Science ®Google Scholar
• RaynerKJSuárezYDávalosAMiR-33 contributes to the regulation of cholesterol homeostasisScience201032859851570157320466885
   PubMed Web of Science ®Google Scholar
• No authors listedClofibrate and niacin in coronary heart diseaseJAMA197523143603811088963
   PubMed Web of Science ®Google Scholar
• BlankenhornDHNessimSAJohnsonRLSanmarcoMEAzenSPCashin-HemphillLBeneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graftsJAMA198725723323332403295315
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med2001345221583159211757504
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation2004110233512351715537681
   PubMed Web of Science ®Google Scholar
• TaylorAJLeeHJSullenbergerLEThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Med Res Opin200622112243225017076985
   PubMed Web of Science ®Google Scholar
• VillinesTCStanekEJDevinePJThe ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment durationJ Am Coll Cardiol201055242721272620399059
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMILUMINATE InvestigatorsEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med2007357212109212217984165
   PubMed Web of Science ®Google Scholar
• BotsMLVisserenFLEvansGWRADIANCE 2 InvestigatorsTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialLancet2007370958215316017630038
   PubMed Web of Science ®Google Scholar
• NissenSETardifJCNichollsSJILLUSTRATE InvestigatorsEffect of torcetrapib on the progression of coronary atherosclerosisN Engl J Med2007356131304131617387129
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGAbtMdal-OUTCOMES InvestigatorsEffects of dalcetrapib in patients with a recent acute coronary syndromeN Engl J Med2012367222089209923126252
   PubMed Web of Science ®Google Scholar
• FayadZAManiVWoodwardMdal-PLAQUE InvestigatorsSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet201137898021547155921908036
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMDetermining the Efficacy and Tolerability InvestigatorsSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]REVEAL: Randomized EValuation of the effects of anacetrapib through lipid-modificationBethesda, MDNational Institutes of Health2010 [updated November 12, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01252953Accessed September 28, 2013
   Google Scholar
• NichollsSJBrewerHBKasteleinJJEffects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trialJAMA2011306192099210922089718
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov [homepage on the Internet]A study of evacetrapib in high-risk vascular disease (ACCELERATE)Bethesda, MDNational Institutes of Health2012 [updated December 19, 2013]. Available from: http://clinicaltrials.gov/show/NCT01687998Accessed September 29, 2013
   Google Scholar
• HeineckeJWThe not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?Nat Med2012181346134722961165
   PubMed Web of Science ®Google Scholar